Cullinan Oncology Q1 2023 Earnings Report
Key Takeaways
Cullinan Oncology reported a net loss of $58.1 million for the first quarter of 2023. The company's cash and investment position was $503.5 million as of March 31, 2023, expected to provide runway into 2026. Enrollment in the zipalertinib pivotal study will now continue at the 100mg BID dose only.
Zipalertinib pivotal trial now enrolling at the 100mg BID dose only.
First clinical data for CLN-049 and CLN-619 to be reported at EHA 2023 Congress and ASCO 2023 Annual Meeting, respectively.
Cash and investment position of $503.5 million as of March 31, 2023, continues to give runway into 2026.
CLN-978 and CLN-617 received FDA clearance of IND applications in the first quarter.
Cullinan Oncology
Cullinan Oncology
Forward Guidance
Cullinan expects its cash resources to provide runway into 2026 based on its current operating plan.